Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 May 13:369:m1361.
doi: 10.1136/bmj.m1361.

Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis

Elpida Vounzoulaki  1   2 , Kamlesh Khunti  3   2 , Sophia C Abner  3   2 , Bee K Tan  4 , Melanie J Davies  3 , Clare L Gillies  3   2
Affiliations
Meta-Analysis

Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis

Elpida Vounzoulaki et al. BMJ. .

Abstract

Objective: To estimate and compare progression rates to type 2 diabetes mellitus (T2DM) in women with gestational diabetes mellitus (GDM) and healthy controls.

Design: Systematic review and meta-analysis.

Data sources: Medline and Embase between January 2000 and December 2019, studies published in English and conducted on humans.

Eligibility criteria for selecting studies: Observational studies investigating progression to T2DM. Inclusion criteria were postpartum follow-up for at least 12 months, incident physician based diagnosis of diabetes, T2DM reported as a separate outcome rather than combined with impaired fasting glucose or impaired glucose tolerance, and studies with both a group of patients with GDM and a control group.

Results: This meta-analysis of 20 studies assessed a total of 1 332 373 individuals (67 956 women with GDM and 1 264 417 controls). Data were pooled by random effects meta-analysis models, and heterogeneity was assessed by use of the I2 statistic. The pooled relative risk for the incidence of T2DM between participants with GDM and controls was estimated. Reasons for heterogeneity between studies were investigated by prespecified subgroup and meta-regression analyses. Publication bias was assessed by funnel plots and, overall, studies were deemed to have a low risk of bias (P=0.58 and P=0.90). The overall relative risk for T2DM was almost 10 times higher in women with previous GDM than in healthy controls (9.51, 95% confidence interval 7.14 to 12.67, P<0.001). In populations of women with previous GDM, the cumulative incidence of T2DM was 16.46% (95% confidence interval 16.16% to 16.77%) in women of mixed ethnicity, 15.58% (13.30% to 17.86%) in a predominantly non-white population, and 9.91% (9.39% to 10.42%) in a white population. These differences were not statistically significant between subgroups (white v mixed populations, P=0.26; white v non-white populations, P=0.54). Meta-regression analyses showed that the study effect size was not significantly associated with mean study age, body mass index, publication year, and length of follow-up.

Conclusions: Women with a history of GDM appear to have a nearly 10-fold higher risk of developing T2DM than those with a normoglycaemic pregnancy. The magnitude of this risk highlights the importance of intervening to prevent the onset of T2DM, particularly in the early years after pregnancy.

Systematic review registration: PROSPERO CRD42019123079.

PubMed Disclaimer

Conflict of interest statement

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: support from the NIHR Applied Research Collaboration East Midlands and NIHR Leicester Biomedical Research Centre for the submitted work. KK has acted as a consultant and speaker for Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Servier, and Merck Sharp and Dohme; has received grants in support of investigator and investigator initiated trials from Novartis, Novo Nordisk, Sanofi-Aventis, Lilly, Pfizer, Boehringer Ingelheim, and Merck Sharp and Dohme; and has received funds for research, honoraria for speaking at meetings and has served on advisory boards for Lilly, Sanofi-Aventis, Merck Sharp and Dohme, and Novo Nordisk. MJD has acted as consultant, advisory board member and speaker for Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp and Dohme, Boehringer Ingelheim, AstraZeneca, and Janssen; as a speaker for Mitsubishi Tanabe Pharma Corporation; and has received grants in support of investigator and investigator initiated trials from Novo Nordisk, Sanofi-Aventis, and Lilly. All other authors declare no competing interests, or activities that could appear to have influenced the submitted work.

Figures

Fig 1
Fig 1
Flow diagram of literature search. GDM=gestational diabetes mellitus; T2DM=type 2 diabetes mellitus
Fig 2
Fig 2
Relative risk of type 2 diabetes mellitus (T2DM) in women with gestational diabetes mellitus (GDM) compared with healthy controls
Fig 3
Fig 3
Relative risk of type 2 diabetes mellitus (T2DM) in women with gestational diabetes mellitus (GDM) and controls by study level ethnicity
Fig 4
Fig 4
Relative risk of type 2 diabetes mellitus (T2DM) in women with gestational diabetes mellitus (GDM) and controls based on study length of follow-up
See this image and copyright information in PMC

Comment in

References

    1. American Diabetes Association Classification and diagnosis of diabetes: standards of medical care in diabetes 2019. Diabetes Care 2019;42(Suppl 1):S13-28. 10.2337/dc19-S002. - DOI - PubMed
    1. International Diabetes Federation IDF Diabetes Atlas - 2019. International Diabetes Federation, 2019. - PubMed
    1. Goueslard K, Cottenet J, Mariet AS, Sagot P, Petit JM, Quantin C. Early screening for type 2 diabetes following gestational diabetes mellitus in France: hardly any impact of the 2010 guidelines. Acta Diabetol 2017;54:645-51. 10.1007/s00592-017-0986-x. - DOI - PubMed
    1. Kim C, Tabaei BP, Burke R, et al. Missed opportunities for type 2 diabetes mellitus screening among women with a history of gestational diabetes mellitus. Am J Public Health 2006;96:1643-8. 10.2105/AJPH.2005.065722. - DOI - PMC - PubMed
    1. Kwong S, Mitchell RS, Senior PA, Chik CL. Postpartum diabetes screening: adherence rate and the performance of fasting plasma glucose versus oral glucose tolerance test. Diabetes Care 2009;32:2242-4. 10.2337/dc09-0900. - DOI - PMC - PubMed